Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal Atrial Fibrillation Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04062071
Recruitment Status : Not yet recruiting
First Posted : August 20, 2019
Last Update Posted : August 20, 2019
Sponsor:
Information provided by (Responsible Party):
chen liujing, Prince of Wales Hospital, Shatin, Hong Kong

Brief Summary:

Atrial fibrillation is a clinically significant cardiac arrhythmia that increases the risk of stroke by 3 to 4 times. Oral anticoagulation has been shown to mitigate stroke risk by two-thirds among patients with AF and is widely recommended in optimizing AF management.Direct oral anticoagulants have also been demonstrated to be superior to warfarin with respect to the risk of fatal bleeding and stroke prevention.

However, the previous study finding highlighted a great gap between current guidelines and the clinical management of AF .Nonetheless, the decision for anticoagulant use is not straightforward.It is worth to investigate the updated prevalence of anticoagulant use, the reasons for not receiving anticoagulant, and the factors independently associated with anticoagulant refusal in patients with non-valvular atrial fibrillation.


Condition or disease Intervention/treatment
Atrial Fibrillation Other: no intervention

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 300 participants
Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 2 Months
Official Title: Prevalence of Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal in Non-valvular Atrial Fibrillation Patients---- A Study in Hong Kong General Out-patient Clinic
Estimated Study Start Date : August 23, 2019
Estimated Primary Completion Date : March 23, 2020
Estimated Study Completion Date : March 23, 2020

Resource links provided by the National Library of Medicine



Intervention Details:
  • Other: no intervention
    no intervention


Primary Outcome Measures :
  1. The prevalence of anticoagulant use in non-valvular atrial fibrillation patients [ Time Frame: August 2019 to March 2020 ]
    calculate the prevalence of anticoagulant use in non-valvular atrial fibrillation patients


Secondary Outcome Measures :
  1. the rate of the refusal of anticoagulant use [ Time Frame: August 2019 to March 2020 ]
    calculate the rate of refusal of anticoagulant use in the eligible non-valvular atrial fibrillation patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
all of the documented atrial fibrillation patients having regular follow up in GOPC in the study period
Criteria

Inclusion Criteria:

  • diagnosis as atrial fibrillation
  • aged ≧18 years
  • able to given consent

Exclusion Criteria:

  • Unable/unwillingness to sign informed consent to study
  • mechanical heart valve
  • moderate-to-severe mitral stenosis
  • Transient atrial fibrillation from reversible cause (e.g., during respiratory tract infection or bronchospasm)
  • pregnancy
  • hospitalization within 1 month prior to inclusion in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04062071


Locations
Layout table for location information
Hong Kong
LIAO, Jiawei Not yet recruiting
Hong Kong, Hong Kong
Contact: LIAO Jiawei    51718217    mirachen2002@gmail.com   
Sponsors and Collaborators
Prince of Wales Hospital, Shatin, Hong Kong

Layout table for additonal information
Responsible Party: chen liujing, resident, Prince of Wales Hospital, Shatin, Hong Kong
ClinicalTrials.gov Identifier: NCT04062071     History of Changes
Other Study ID Numbers: version1 last update 30/7/2019
First Posted: August 20, 2019    Key Record Dates
Last Update Posted: August 20, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: no Conflict of interest

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by chen liujing, Prince of Wales Hospital, Shatin, Hong Kong:
anticoagulants
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Anticoagulants